Anthony Wile, CEO of PharmaCielo Ltd. (“the Company”) is pleased to announce that David Gordon has been appointed its Chief Corporate Officer (CCO) effective October 1, 2018.

As CCO, Mr. Gordon will be responsible for overseeing and managing relationships with news media, analysts, shareholders and regulators in addition to ensuring alignment in achieving corporate responsibility and development objectives across international operations.


David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)
David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)

“David has been an essential advisor to PharmaCielo since the earliest days of its establishment, guiding us on effective communication and corporate development strategies,” said Anthony Wile.  “As we build out our global infrastructure, I am delighted that he has agreed to bring his impressive track record and range of experience to the table on a permanent basis to help us to continue the growth and expansion of PharmaCielo throughout both the Colombian and international marketplace.”

Previously Mr. Gordon was a principal advisor to PharmaCielo as Managing Partner of Cohn & Wolfe | Canada, one of Canada’s leading communication strategy firms, and since 2013 has served as Chair of the Canadian Council of PR Firms.  Mr. Gordon was appointed to the Board of Directors of PharmaCielo Ltd. in 2016 and is a member of the Institute of Corporate Directors (ICD).

“Working with PharmaCielo and the executive team for the past several years has been an exciting period.  The emergence of a new industry that challenges convention on multiple levels including international trade, public policy and communication, to name but a few, encapsulates the various fields of challenge I have experienced throughout my career,” said David Gordon. “I look forward to continuing to work with my colleagues in Canada and Colombia to help expand to the global market the leadership that PharmaCielo has demonstrated in the Colombian marketplace.”

With 20-plus years of experience in corporate strategy and brand communications, combined with a background in public policy and political strategy following a career start in international trade and combined with an MA and MBA, David Gordon is a strong believer in being an engaged member of the community and has served on the boards of a number of non-profit organizations.

About PharmaCielo

PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.

For further information:

www.PharmaCielo.com  

For further information: Media Relations: David Gordon, Tel: +1 647 259 3258, d.gordon@pharmacielo.ca; (Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776, Juan.M.Cuellar@Sprgroup.biz

Source: www.newswire.ca

CanBud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“CanBud” or the “Corporation”) is pleased to announce that it has closed the final tranche of its oversubscribed non-brokered private placement for aggregate gross proceeds of approximately $4,730,000 (the “Offering”).

The Corporation issued a combined total of 39,409,346 units (each a “Unit“) at price of $0.12 per Unit, with each Unit comprised of one common share in the capital of the Corporation (each a “Common Share“) and one common share purchase warrant (each a “Warrant“). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.22 within 24 months of the closing of the Offering (the “Warrant Term“), provided, however that if the closing price of the Common Shares on the Canadian Securities Exchange (the “CSE“) (or any such other stock exchange in Canada as the Common Shares may trade at the applicable time) is $0.25 or greater per Common Share for a period of five (5) consecutive trading days at any time after the closing date of the Offering, the Corporation may accelerate the Warrant Term such that the Warrants shall expire on the date which is 30 days following the date a press release is issued by the Corporation announcing the reduced warrant terms.

Keep reading... Show less

Thoughtful Brands Inc. (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) (the “Company” or “Thoughtful Brands) announces that the letter of intent with Franchise Cannabis Corp. (“FCC”), previously announced in January, has been terminated. The previously announced European joint venture with FCC will continue and allow the Company to launch and tailor its products to European consumer demands

In connection with termination of the merger transaction with FCC, the Company has agreed to pay FCC $100,000 in cash and to issue FCC 5,000,000 common shares of the Company at a deemed value of $0.05 per share. The common shares will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws.

Keep reading... Show less

Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.

Keep reading... Show less

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).

Keep reading... Show less

Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.

Keep reading... Show less